UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Oncotarget, 2018-03, Vol.9 (17), p.13796-13806

2018

Link zum Volltext

Verfügbarkeit prüfen

A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog

Journal of immunological methods, 2023-12, Vol.523, p.113575-113575, Article 113575

2023

Link zum Volltext

Verfügbarkeit prüfen

Cross-Reactive Polyclonal Antibodies Raised Against GalNAc-Conjugated siRNA Recognize Mostly the GalNAc Moiety

The AAPS journal, 2024-04, Vol.26 (3), p.41-41

2024

Link zum Volltext

Verfügbarkeit prüfen

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth

Clinical cancer research, 2014-12, Vol.20 (23), p.6059-6070

2014

Link zum Volltext

Verfügbarkeit prüfen

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Investigational new drugs, 2013-08, Vol.31 (4), p.833-844

2013

Link zum Volltext

Verfügbarkeit prüfen

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

Investigational new drugs, 2018-08, Vol.36 (4), p.536-544

2018

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Tumor Growth and Metastasis in Non―Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Clinical cancer research, 2013-10, Vol.19 (20), p.5699-5710

2013

Link zum Volltext

Verfügbarkeit prüfen

Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed : a phenotype partially reversed by selective estrogen receptor modulators

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (15), p.6593-6600

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract 528: Evaluation of single agent merestinib (LY2801653) or emibetuzumab (LY2875358) and the combination in a xenograft tumor model bearing MET exon 14 skipping

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.528-528

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1823: Characterization of the anti-angiogenic properties of merestinib (LY2801653), an oncokinase inhibitor

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1823-1823

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5590-5590

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.519-519

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing TPM3-NTRK1 fusion

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2647-2647

2016

Link zum Volltext

Verfügbarkeit prüfen

CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e18558-e18558

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3042-3042

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4403-4403

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1738-1738

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract A47: Circulating tumor cell (CTC) assay development for detection of phosphohistone H3 (pHH3) as a clinical pharmacodynamic (PD) marker for LY2523355, an Eg5 kinesin inhibitor

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A47-A47

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2087: Detection of KRAS mutations in circulating tumor cells (CTCs) and in formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR method

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2087-2087

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2339-2339

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A49-A49

2011

Link zum Volltext

Verfügbarkeit prüfen

Mature Chief Cells Are Cryptic Progenitors for Metaplasia in the Stomach

Gastroenterology (New York, N.Y. 1943), 2010-12, Vol.139 (6), p.2028-2037.e9

2010

Link zum Volltext

Verfügbarkeit prüfen

Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis

The lancet. Gastroenterology & hepatology, 2021-07, Vol.6 (7), p.547-558

2021

Link zum Volltext

Verfügbarkeit prüfen

Akt Activation, but not Extracellular Signal–Regulated Kinase Activation, Is Required for SDF-1α/CXCR4–Mediated Migration of Epitheloid Carcinoma Cells

Molecular cancer research, 2005-04, Vol.3 (4), p.227-236

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog

Cross-Reactive Polyclonal Antibodies Raised Against GalNAc-Conjugated siRNA Recognize Mostly the GalNAc Moiety

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

Inhibition of Tumor Growth and Metastasis in Non―Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed : a phenotype partially reversed by selective estrogen receptor modulators

Abstract 528: Evaluation of single agent merestinib (LY2801653) or emibetuzumab (LY2875358) and the combination in a xenograft tumor model bearing MET exon 14 skipping

Abstract 1823: Characterization of the anti-angiogenic properties of merestinib (LY2801653), an oncokinase inhibitor

Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model

Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models

Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing TPM3-NTRK1 fusion

CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts)

Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2

Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models

Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors

Abstract A47: Circulating tumor cell (CTC) assay development for detection of phosphohistone H3 (pHH3) as a clinical pharmacodynamic (PD) marker for LY2523355, an Eg5 kinesin inhibitor

Abstract 2087: Detection of KRAS mutations in circulating tumor cells (CTCs) and in formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR method

Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples

Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors

Mature Chief Cells Are Cryptic Progenitors for Metaplasia in the Stomach

Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis

Akt Activation, but not Extracellular Signal–Regulated Kinase Activation, Is Required for SDF-1α/CXCR4–Mediated Migration of Epitheloid Carcinoma Cells

Suchergebnisse filtern